• Positive RNAi results Silences critics

    September 21, 2017 | Posted by

    By Richard Gill, CFA It’s good news for the RNA interference industry as US listed market leader Alnylam Pharmaceuticals (NASDAQ:ALNY) announced positive results this week from its Phase 3 study of nerve disorder drug patisiran. This is a very positive development for an industry which has promised much but seen numerous challenges over the past few […]

  • Silence Therapeutics – patent claim highlights multi million pound licence potential

    July 11, 2017 | Posted by

    By Richard Gill CFA In our initiation of coverage report on AIM listed RNA therapeutics specialist Silence Therapeutics (SLN) we highlighted the firm’s potentially valuable patent portfolio. Realising that value for shareholders might have come one step closer after the firm announced last week that it has issued a claim in the UK High Courts […]

  • Silence Therapeutics – Expansion of Intellectual Property portfolio supports further long-term value

    May 16, 2017 | Posted by

    By Richard Gill, CFA The AIM listed RNA therapeutics specialist Silence Therapeutics (SLN) has announced a significant expansion of its chemical modification patent estate. In March this year the company revealed that the European Patent Office had granted a patent covering key RNAi chemical modifications, thus giving it further protection for its technology across many […]

  • Silence Therapeutics Plc – New Conviction Buy stance

    March 11, 2017 | Posted by

    RNAi specialist with valuable embedded IP and prospective clinical trials positioned at the heart of an anticipated wave of consolidation within the sector Silence Therapeutics is an AIM listed biotechnology company focused on the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need. Described as being […]